These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21726878)

  • 1. The effect of FTY720 in the Theiler's virus model of multiple sclerosis.
    Li L; Matsumoto M; Seabrook TJ; Cojean C; Brinkman V; Pachner AR
    J Neurol Sci; 2011 Sep; 308(1-2):41-8. PubMed ID: 21726878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Theiler's virus-induced demyelinating disease with teriflunomide.
    Gilli F; Li L; Royce DB; DiSano KD; Pachner AR
    J Neurovirol; 2017 Dec; 23(6):825-838. PubMed ID: 28913765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-secreting cells in the central nervous system in an animal model of MS: Phenotype, association with disability, and in vitro production of antibody.
    Pachner AR; Brady J; Narayan K
    J Neuroimmunol; 2007 Oct; 190(1-2):112-20. PubMed ID: 17919740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K; Adachi K
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
    Johnson TA; Lapierre Y; Bar-Or A; Antel JP
    Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system-directed effects of FTY720 (fingolimod).
    Miron VE; Schubart A; Antel JP
    J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
    Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
    Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
    Radue EW; O'Connor P; Polman CH; Hohlfeld R; Calabresi P; Selmaj K; Mueller-Lenke N; Agoropoulou C; Holdbrook F; de Vera A; Zhang-Auberson L; Francis G; Burtin P; Kappos L;
    Arch Neurol; 2012 Oct; 69(10):1259-69. PubMed ID: 22751847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ameliorating effects of anti-Dll4 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease.
    Takeichi N; Yanagisawa S; Kaneyama T; Yagita H; Jin YH; Kim BS; Koh CS
    Int Immunol; 2010 Sep; 22(9):729-38. PubMed ID: 20685674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
    Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A; Montalban X
    Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of the peripheral blood CD56(bright) NK lymphocyte subset in FTY720-treated multiple sclerosis patients.
    Johnson TA; Evans BL; Durafourt BA; Blain M; Lapierre Y; Bar-Or A; Antel JP
    J Immunol; 2011 Jul; 187(1):570-9. PubMed ID: 21622858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW; Choi JW; Chun J
    Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
    Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
    J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod for multiple sclerosis.
    Pelletier D; Hafler DA
    N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
    [No Abstract]   [Full Text] [Related]  

  • 20. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
    Kipp M; Amor S
    Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.